ATE540694T1 - Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig - Google Patents

Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig

Info

Publication number
ATE540694T1
ATE540694T1 AT01996390T AT01996390T ATE540694T1 AT E540694 T1 ATE540694 T1 AT E540694T1 AT 01996390 T AT01996390 T AT 01996390T AT 01996390 T AT01996390 T AT 01996390T AT E540694 T1 ATE540694 T1 AT E540694T1
Authority
AT
Austria
Prior art keywords
ivig
monoclonal
treating thrombocytopenia
thrombocytopenia
composition
Prior art date
Application number
AT01996390T
Other languages
English (en)
Inventor
Alan Lazarus
John Freedman
Seng Song
Andrew Crow
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Application granted granted Critical
Publication of ATE540694T1 publication Critical patent/ATE540694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01996390T 2000-11-20 2001-11-20 Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig ATE540694T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24944100P 2000-11-20 2000-11-20
PCT/CA2001/001648 WO2002040047A2 (en) 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig

Publications (1)

Publication Number Publication Date
ATE540694T1 true ATE540694T1 (de) 2012-01-15

Family

ID=22943488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996390T ATE540694T1 (de) 2000-11-20 2001-11-20 Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig

Country Status (7)

Country Link
US (1) US20040047862A1 (de)
EP (2) EP2283861B1 (de)
AT (1) ATE540694T1 (de)
AU (1) AU2002220404A1 (de)
CA (2) CA2467781C (de)
DK (2) DK2283861T3 (de)
WO (1) WO2002040047A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1737487B1 (de) * 2004-03-30 2016-05-25 Canadian Blood Services Verfahren zur behandlung von autoimmunkrankheiten mit antikörpern
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8597636B2 (en) 2006-01-13 2013-12-03 Canadian Blood Services Method for treating autoimmune diseases and compositions therefor
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
WO2014093417A1 (en) * 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
CA2978253A1 (en) 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025229206A1 (en) 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
JPH0987202A (ja) * 1995-09-20 1997-03-31 Sumitomo Pharmaceut Co Ltd 血液凝固異常治療剤
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
WO2000067796A1 (en) * 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells

Also Published As

Publication number Publication date
US20040047862A1 (en) 2004-03-11
CA2467781C (en) 2014-09-23
EP1370288B1 (de) 2012-01-11
EP2283861A3 (de) 2013-05-29
EP1370288A2 (de) 2003-12-17
DK1370288T3 (da) 2012-03-05
EP2283861B1 (de) 2016-01-27
DK2283861T3 (en) 2016-02-15
CA2856033A1 (en) 2002-05-23
CA2467781A1 (en) 2002-05-23
EP2283861A2 (de) 2011-02-16
WO2002040047A2 (en) 2002-05-23
CA2856033C (en) 2015-11-03
AU2002220404A1 (en) 2002-05-27
WO2002040047A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
ATE540694T1 (de) Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
DE60229059D1 (de) Proteomimetische verbindungen und verfahren
ATE458491T1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
TW200621802A (en) Fully human monoclonal antibodies to IL-13
ATE447587T1 (de) Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
DE60328195D1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
HRP20110758T1 (en) Il-17 antagonistic antibodies
EP1337275A4 (de) Verfahren zur verbesserung der wirksamkeit von zytotoxischen mitteln durch verwendung von hsp90-hemmern
TNSN06080A1 (en) Antibodies to m-csf
MA28430B1 (fr) Anticorps a madcam.
PL370514A1 (en) Antibodies to cd40
SG142330A1 (en) Anti-cd38 human antibodies and uses therefor
TNSN07394A1 (en) Antibodies to myostatin
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
DK3284753T3 (da) Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
DE602005020743D1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE377657T1 (de) Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
ATE439381T1 (de) Reinigung von polyreaktiven autoantikörpern und deren verwendungen
RU2019103991A (ru) Анти-il-22r-антитела
RU2011104709A (ru) Фармацевтическая композиция для лечения и предупреждения рака
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge